Drug Profile
Research programme: drug discovery - Curia/Bristol-Myers Squibb
Alternative Names: Natural products-based drugsLatest Information Update: 13 Oct 2021
Price :
$50
*
At a glance
- Originator Albany Molecular Research; Bristol-Myers Squibb
- Developer AMRI; Bristol-Myers Squibb
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 31 Dec 2008 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
- 22 Dec 2008 AMRI and Bristol-Myers Squibb conclude their two-year collaboration on the discovery of natural products-based drugs for various Undefined indications
- 02 May 2007 Albany Molecular Research is now called AMRI